Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment
Primary result · Major microvascular events (rs7403531)Result — go to the resultHazard ratio 0.41 95% CI 0.21–0.80Authors' conclusion
We found that patients with G allele of RASGRP1 (rs56254815) showed a better antihypertensive therapy efficacy in T2DM patients. The rs7403531 T allele could reduce the risk of major microvascular events and major eye diseases in T2DM patients receiving either hypoglycemic or antihypertensive therapy. Our findings suggest that RASGRP1 genetic polymorphism might predict the cardiovascular complications in T2DM patients.
Study context
- Population
- Chinese patients with high-risk T2DM receiving glycemic control and antihypertensive treatment in a multicenter drug clinical study cohortmean follow-up 4.8 years
- Participants
- 1,357 patients
- Comparison
- RASGRP1 rs7403531 CT/TT vs CC genotype
- Primary endpoint
- Major vascular endpoint events: CV death, non-fatal stroke, coronary heart disease, new-onset or worsening renal disease and DR
- Follow-up
- For 5 years
Methodological detailsmulticenter, 2 × 2 factorial (glucose control axis and blood pressure lowering axis), retrospective analysis
- Multicenter
- 2 × 2 factorial (glucose control axis and blood pressure lowering axis)
- Retrospective analysis
Primary result
Major microvascular events (rs7403531)
Hazard ratio
0.41
95% CI 0.21–0.80
P = 0.009
As reported in the abstract
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Major eye disease events (rs7403531)CT/TTvs CC | 0.44 (0.20–0.94) | P = 0.03 | |
| Secondary nephropathy, standard glycemic control (rs7403531)CT/TTvs CC | 0.48 (0.25–0.92) | P = 0.03 | |
| All cerebrovascular events, placebo group of BP lowering axis (rs7403531)CCvs CT/TT | 2.24 (1.11–4.51) | P = 0.025 | |
| Stroke events, placebo group of BP lowering axis (rs7403531)CCvs CT/TT | 2.07 (1.03–4.15) | P = 0.04 | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Estimate | P value |
|---|---|---|
| Systolic BP, antihypertensive group (rs56254815)AG/GG vs AA · lower with AG/GG (decreased on average) | difference 1.5 mmhg | P = 0.04 |
| BP, placebo group (rs56254815)AG/GG vs AA | difference 1.7 mmHg | P = 0.02 |
Major cerebrovascular events, CC genotype in antihypertensive group (rs7403531)
- Reduced risk of major cerebrovascular events in CC carriers in antihypertensive group, HR
- 0.36 (95% CI 0.15-0.86, P = 0.021)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →